Follow-on roundup: Ascendis, Sarepta

Ascendis and Sarepta each priced follow-ons, raising $500 million and $375 million, respectively, after the bell Tuesday. Invitae and CymaBay also priced follow-ons.

Ascendis Pharma A/S (NASDAQ:ASND) raised $500 million through the sale of 4.2 million

Read the full 355 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE